Waters (WAT) 10-K risk factor changes: FY2019 vs FY2018
The 2019-12-31 10-K against the 2018-12-31 one, compared heading by heading and sentence by sentence. One of these filings carries no fiscal year tag, so its year is the calendar year of the period end.
Item 1A0 rewritten177 added0 removed0 unchanged
All filing items599 rewritten2,246 added1,864 removed426 unchanged
Summary
counted, not written
- Item 1A headings could not be compared: the parser did not find an Item 1A in both filings.
- Sentence by sentence, 2,246 added, 1,864 removed, 599 rewritten and 426 unchanged across 22 items that differ.
- New this year: Item 1A. Risk Factors.
- Not in this year's filing: Item 1B. Unresolved Staff Comments; Item 8. Financial Statements and Supplementary Data; Item 9B. Other Information; Item 13. Certain Relationships and Related Transactions and Director Independence; Item 14. Principal Accountant Fees and Services; Item 16. Form 10-K Summary.
Sentences by item
22 items, with every count and a link to each item that changed
Underlined words on a shaded ground are new in FY2019; struck-through words were in FY2018. Sentences that are wholly new or wholly gone are labelled rather than marked.
Item 1A. Risk Factors
0 rewritten, 177 added, 0 removed, 0 unchanged
New section this year
Read the full itemFY2019 item · filed February 25, 2020
Risk Factors
The Company is subject to risks and uncertainties, including, but not limited to, the following:
The Company’s international operations may be negatively affected by political events, wars or terrorism and regulatory changes, related to either a specific country or a larger region.
These potential political, currency and economic disruptions, as well as foreign currency exchange rate fluctuations, could have a material adverse effect on the Company’s results of operations or financial condition.
Approximately 71% and 72% of the Company’s net sales in 2019 and 2018, respectively, were outside of the United States and were primarily denominated in foreign currencies.
In addition, the Company has considerable manufacturing operations in Ireland and the U.K., as well as significant subcontractors located in Singapore.
As a result, a significant portion of the Company’s sales and operations are subject to certain risks, including adverse developments in the political, regulatory and economic environment, in particular, uncertainty regarding possible changes to foreign and domestic trade policy; the effect of the U.K.’s exit from the European Union as well as the financial difficulties and debt burden experienced by a number of European countries; the instability and potential impact of war or terrorism; the instability and possible dissolution of the Euro as a single currency; sudden movements in a country’s foreign exchange rates due to a change in a country’s sovereign risk profile or foreign exchange regulatory practices; tariffs and other trade barriers; the impact of public health epidemics, such as the coronavirus currently impacting China and elsewhere; difficulties in staffing and managing foreign operations; and associated adverse operational, contractual and tax consequences.
Additionally, the U.S. dollar value of the Company’s net sales, cost of sales, operating expenses, interest, taxes and net income varies with foreign currency exchange rate fluctuations.
Significant increases or decreases in the value of the U.S. dollar relative to certain foreign currencies, particularly the Euro, Japanese yen and British pound, could have a material adverse effect or benefit on the Company’s results of operations or financial condition.
Global economic conditions may decrease demand for the Company’s products and harm the Company’s financial results.
The Company is a global business that may be adversely affected by changes in global economic conditions.
These changes in global economic conditions, both inside and outside the U.S., may affect the demand for the Company’s products and services.
This may result in a decline in sales in the future, increased rate of order cancellations or delays, increased risk of excess or obsolete inventories, longer sales cycles and potential difficulty in collecting sales proceeds.
There can be no assurance regarding demand for the Company’s products and services in the future.
The Company’s financial results are subject to changes in customer demand, which may decrease for a number of reasons, many beyond the Company’s control.
The demand for the Company’s products is dependent upon the size of the markets for its LC,
LC-MS,
thermal analysis, rheometry and calorimetry products; the timing and level of capital spending and expenditures of the Company’s customers; changes in governmental regulations, particularly affecting drug, food and drinking water testing; funding available to academic, governmental and research institutions; general economic conditions and the rate of economic growth in the Company’s major markets; and competitive considerations.
The Company typically experiences an increase in sales in its fourth quarter as a result of purchasing habits for capital goods by customers that tend to exhaust their spending budgets by calendar year end.
However, there can be no assurance that the Company will effectively forecast customer demand and appropriately allocated research and development expenditures to products with high growth and high margin prospects.
Additionally, there can be no assurance that the Company’s results of operations or financial condition will not be adversely impacted by a change in any of the factors listed above or the continuation of uncertain global economic conditions.
Additionally, the analytical instrument market may, from time to time, experience low sales growth.
Approximately 57% and 56% of the Company’s net sales in 2019 and 2018, respectively, were to worldwide pharmaceutical and biotechnology companies, which may be periodically subject to unfavorable market conditions and consolidations.
Unfavorable industry conditions could have a material adverse effect on the Company’s results of operations or financial condition.
Disruption in worldwide financial markets could adversely impact the Company’s access to capital and financial condition.
Financial markets in the U.S., Europe and Asia have experienced times of extreme disruption, including, among other things, sharp increases in the cost of new capital, credit rating downgrades and bailouts, severely diminished capital availability and severely reduced liquidity in money markets.
Financial and banking institutions have also experienced disruptions, resulting in large asset write-downs, higher costs of capital, rating downgrades and reduced desire to lend money.
There can be no assurance that there will not be future deterioration or prolonged disruption in financial markets or financial institutions.
Any future deterioration or prolonged disruption in financial markets or financial institutions in which the Company participates may impair the Company’s ability to access its existing cash, utilize its existing syndicated bank credit facility funded by such financial institutions, and impair its ability to access sources of new capital.
The cost to the Company of any new capital raised and interest expense would increase if this were to occur.
Competitors may introduce more effective or less expensive products than the Company’s, which could result in decreased sales.
The competitive landscape may transform as a result of potential changes in ownership, mergers and continued consolidations among the Company’s competitors, which could harm the Company’s business.
The analytical instrument market and, in particular, the portion related to the Company’s HPLC, UPLC,
LC-MS,
thermal analysis, rheometry and calorimetry product lines, is highly competitive and subject to rapid changes in technology.
The Company encounters competition from several international instrument suppliers and other companies in both domestic and foreign markets.
Some competitors have instrument businesses that are generally more diversified than the Company’s business, but are typically less focused on the Company’s chosen markets.
Over the years, some competitors have merged with other competitors for various reasons, including increasing product line offerings, improving market share and reducing costs.
There can be no assurance that the Company’s competitors will not introduce more effective and less costly products than those of the Company or that the Company will be able to increase its sales and profitability from new product introductions.
There can be no assurance that the Company’s sales and marketing forces will compete successfully against the Company’s competitors in the future.
An excerpt. Shown here: all 0 rewritten, 40 of 177 added and all 0 removed. The counts are complete. For every sentence, read Item 1A. Risk Factors in the FY2019 filing.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
248 rewritten, 122 added, 130 removed, 160 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
[removed: Business] [added: Business] and Financial [removed: Overview][added: Overview]
The Company has two operating segments: [removed: WatersTM and TATM.][added: Waters]
[removed: Waters products and services primarily consist of high performance liquid chromatography (“HPLC”), ultra performance liquid chromatography (“UPLCTM”] [added: ”] and together with HPLC, referred to as “LC”), mass spectrometry (“MS”) and precision chemistry consumable products and related services.
The Company’s operating results are as follows for the years ended December 31, [removed: 2018, 2017] [added: 2019, 2018] and [removed: 2016] [added: 2017] (dollars in thousands, except per share data):
| | | [removed: Year] [added: Year] Ended December [removed: 31,] [added: 31,] | | | | | | | | | | | | [removed: _% change_] [added: % change] | | | | | | |
| | | [removed: 2018] [added: 2019] | | | | [removed: 2017] [added: 2018] | | | | [removed: 2016] [added: 2017] | | | | [removed: _2018] [added: 2019] vs. [removed: 2017_] [added: 2018] | | | | [removed: _2017] [added: 2018] vs. [removed: 2016_] [added: 2017] | | |
| Product sales | | $ | [removed: 1,604,993] [added: 1,567,189] | | | $ | [removed: 1,552,349] [added: 1,604,993] | | | $ | [removed: 1,460,296] [added: 1,552,349] | | | | [removed: _3_] [added: (2] | [removed: _%_] [added: %)] | | | [removed: _6_] [added: 3] | [removed: _%_] [added: %] |
| Service sales | | | [removed: 814,936] [added: 839,407] | | | | [removed: 756,729] [added: 814,936] | | | | [removed: 707,127] [added: 756,729] | | | | [removed: _8_] [added: 3] | [removed: _%_] [added: %] | | | [removed: _7_] [added: 8] | [removed: _%_] [added: %] |
| Total net sales | | | [removed: 2,419,929] [added: 2,406,596] | | | | [removed: 2,309,078] [added: 2,419,929] | | | | [removed: 2,167,423] [added: 2,309,078] | | | | [removed: _5_] [added: (1] | [removed: _%_] [added: %)] | | | [removed: _7_] [added: 5] | [removed: _%_] [added: %] |
| Cost of sales | | | [removed: 992,564] [added: 1,010,700] | | | | [removed: 947,067] [added: 992,564] | | | | [removed: 891,453] [added: 947,067] | | | | [removed: _5_] [added: 2] | [removed: _%_] [added: %] | | | [removed: _6_] [added: 5] | [removed: _%_] [added: %] |
| Selling and administrative expenses | | | [removed: 536,902] [added: 534,791] | | | | [removed: 544,363] [added: 536,902] | | | | [removed: 512,331] [added: 544,363] | | | | [removed: _(1_] [added: —] | [removed: _%)_] | | | [removed: _6_] [added: (1] | [removed: _%_] [added: %)] |
| Research and development expenses | | | [removed: 143,403] [added: 142,955] | | | | [removed: 132,593] [added: 143,403] | | | | [removed: 125,187] [added: 132,593] | | | | [removed: _8_] [added: —] | [removed: _%_] | | | [removed: _6_] [added: 8] | [removed: _%_] [added: %] |
| Purchased intangibles amortization | | | [removed: 7,712] [added: 9,693] | | | | [removed: 6,743] [added: 7,712] | | | | [removed: 9,889] [added: 6,743] | | | | [removed: _14_] [added: 26] | [removed: _%_] [added: %] | | | [removed: _(32_] [added: 14] | [removed: _%)_] [added: %] |
| Litigation (settlement) provision | | | [removed: (426] [added: —] | [removed: )] | | | [removed: 11,114] [added: (426] | [added: )] | | | [removed: 3,524] [added: 11,114] | | | | [removed: _(104_] [added: 100] | [removed: _%)_] [added: %] | | | [removed: _215_] [added: (104] | [removed: _%_] [added: %)] |
| Acquired in-process research and development | | | — | | | | [removed: 5,000] [added: —] | | | | [removed: —] [added: 5,000] | | | | [removed: _(100_] [added: —] | [removed: _%)_] | | | [removed: _—_] [added: (100] | [added: %)] |
| Operating income | | | [removed: 739,774] [added: 708,457] | | | | [removed: 662,198] [added: 739,774] | | | | [removed: 625,039] [added: 662,198] | | | | [removed: _12_] [added: (4] | [removed: _%_] [added: %)] | | | [removed: _6_] [added: 12] | [removed: _%_] [added: %] |
| [removed: _Operating] [added: Operating] income as a % of [removed: sales_] [added: sales] | | | [removed: _30.6_] [added: 29.4] | [removed: _%_] [added: %] | | | [removed: _28.7_] [added: 30.6] | [removed: _%_] [added: %] | | | [removed: _28.8_] [added: 28.7] | [removed: _%_] [added: %] | | | | | | | | |
| Other expense | | | [removed: (47,794] [added: (3,586] | ) | | | [removed: (340] [added: (47,794] | ) | | | [removed: (700] [added: (340] | ) | | | [removed: _*_] | [removed: _*_] | | | [removed: _51_] | [removed: _%_] |
| Interest expense, net | | | [removed: (9,834] [added: (26,632] | ) | | | [removed: (20,761] [added: (9,834] | ) | | | [removed: (24,225] [added: (20,761] | ) | | | [removed: _(53_] [added: 171] | [removed: _%)_] [added: %] | | | [removed: _(14_] [added: (53] | [removed: _%)_] [added: %)] |
| Income before income taxes | | | [removed: 682,146] [added: 678,239] | | | | [removed: 641,097] [added: 682,146] | | | | [removed: 600,114] [added: 641,097] | | | | [removed: _6_] [added: (1] | [removed: _%_] [added: %)] | | | [removed: _7_] [added: 6] | [removed: _%_] [added: %] |
| Provision for income taxes | | | [removed: 88,352] [added: 86,041] | | | | [removed: 620,786] [added: 88,352] | | | | [removed: 78,611] [added: 620,786] | | | | [removed: _(86_] [added: (3] | [removed: _%)_] [added: %)] | | | [removed: _690_] [added: (86] | [removed: _%_] [added: %)] |
| Net income | | $ | [removed: 593,794] [added: 592,198] | | | $ | [removed: 20,311] [added: 593,794] | | | $ | [removed: 521,503] [added: 20,311] | | | | [removed: _*_] [added: —] | [removed: _*_] | | | [removed: _(96_] | [removed: _%)_] |
| Net income per diluted common share | | $ | [removed: 7.65] [added: 8.69] | | | $ | [removed: 0.25] [added: 7.65] | | | $ | [removed: 6.41] [added: 0.25] | | | | [removed: _*_] [added: 14] | [removed: _*_] [added: %] | | | [removed: _(96_] | [removed: _%)_] |
[removed: |] [removed: |] Percentage not meaningful [removed: |]
The Company’s net sales [removed: increased 5%] [added: decreased approximately 1%] in [removed: 2018] [added: 2019] as compared to [removed: 2017,] [added: 2018,] and [removed: 7%] [added: increased 5%] in [removed: 2017] [added: 2018] as compared to [removed: 2016.][added: 2017.]
Foreign currency translation [added: decreased sales by 2% in 2019 and] increased sales [removed: growth] by 1% in [removed: both 2018 and 2017.][added: 2018.]
Instrument system sales [added: decreased 4% and] increased 2% [removed: and 6%] in [removed: 2018] [added: 2019] and [removed: 2017,] [added: 2018,] respectively.
Recurring revenues (combined sales of precision chemistry consumables and services) increased [removed: 8%] [added: 3%] and [removed: 7%] [added: 8%] in [removed: 2018] [added: 2019] and [removed: 2017,] [added: 2018,] respectively, as a result of a larger installed base of customers and higher billing demand for service sales.
[removed: Geographically, the] [added: The] Company’s sales growth in [removed: both] 2018 [removed: and 2017] was primarily driven by the 7% [removed: and 10%] sales growth in Asia, [removed: respectively,] with [removed: double-digit] [added: China’s] sales [removed: growth in China for both years.][added: growing 15%.]
Sales to pharmaceutical customers [added: were flat in 2019 and] grew 5% [removed: and 7%] in [removed: 2018 and 2017, respectively.][added: 2018.]
[removed: These increases were driven by] [added: Offsetting those declines was an increase in] the [removed: increasing] need for global access to prescription drugs and the testing of newer and [removed: more] complex biologic drugs.
Combined sales to industrial customers, which include [removed: materials] [added: material] characterization, food, environmental and fine chemical markets, [removed: grew] [added: declined] 2% [removed: and 4%] in [removed: 2018] [added: 2019] and [removed: 2017, respectively.][added: grew 2% in 2018.]
Combined sales to [removed: governmental and] academic [added: and governmental] customers increased [added: 2% in 2019 and] 8% in [removed: both 2018] [added: 2018, with the effect of foreign currency translation decreasing sales by 1% in 2019] and [removed: 2017.][added: increasing sales by 1% in 2018.]
Sales to [removed: governmental and] academic [added: and governmental] customers are highly dependent on when institutions receive funding to purchase our instrument systems and, as such, sales growth rates can vary significantly from period to period.
Operating income [removed: was $740 million in 2018, an increase of] [added: increased] 12% [added: in 2018] as compared to 2017.
The Company’s effective tax rates were [removed: 13.0%, 96.8%] [added: 12.7%, 13.0%] and [removed: 13.1%] [added: 96.8%] for [removed: 2018, 2017] [added: 2019, 2018] and [removed: 2016,] [added: 2017,] respectively.
Net income per diluted share was [removed: $7.65, $0.25] [added: $8.69, $7.65] and [removed: $6.41] [added: $0.25] in [removed: 2018, 2017] [added: 2019, 2018] and [removed: 2016,] [added: 2017,] respectively.
The Company generated [removed: $604] [added: $643] million, [removed: $698] [added: $604] million and [removed: $643] [added: $698] million of net cash flows from operations in [removed: 2018, 2017] [added: 2019, 2018] and [removed: 2016,] [added: 2017,] respectively.
The [removed: decrease] [added: increase] in operating cash flow in [removed: 2018] [added: 2019] was primarily a result of [added: payments made in 2018 that did not recur, including] $103 million of income tax payments made in the U.S. relating to the Company’s estimated 2017 transition tax liability and 2018 estimated tax payments, a $15 million litigation settlement payment and $11 million of contributions to certain defined benefit pension plans.
Over the next [removed: four] [added: three] years, the Company is required to make annual U.S. federal tax payments of approximately $38 million to tax authorities in connection with the Company’s estimated [added: remaining] transition tax liabilities of [removed: $433] [added: $404] million under the 2017 Tax Act.
TM
and TA
TM
Waters products and services primarily consist of high performance liquid chromatography (“HPLC”), ultra performance liquid chromatography (“UPLC
TM
In 2019, the decrease in instrument system sales was primarily driven by weaker demand for our products by our customers due to uncertainty caused by macroeconomic conditions and governmental policy changes.
Foreign currency translation decreased instrument system sales by 1% in 2019 and increased instrument system sales by 1% in 2018.
Recurring revenues were impacted by foreign currency, which decreased sales by 2% in 2019 and increased sales by 2% in 2018.
Geographically, the decline in the Company’s sales in 2019 was a result of increased sales in the U.S., Canada, Japan and the rest of Asia being offset by a decrease in sales in other geographies on weaker demand for our products due to uncertainty caused by macroeconomic conditions, primarily from Brexit as well as Latin America, and governmental policy changes in China.
In addition, the effect of foreign currency translation negatively impacted sales by 2% overall.
Sales in Europe decreased 4% in 2019 and increased 4% in 2018.
In 2019, Europe sales were impacted by weak demand in Western Europe caused by the political uncertainties of Brexit and the effect of foreign currency translation, which reduced sales by 4% in 2019 and increased sales by 3% in 2018.
Sales in the Americas decreased 1% in 2019 and increased 3% in 2018.
The Americas sales in 2019 were negatively impacted by macroeconomic conditions in Latin America, and the 2018 Americas sales growth can be attributed to the increase in sales after the lower customer demand stemming from the 2017 natural disasters in the U.S., Mexico and Puerto Rico.
Sales to pharmaceutical customers in 2019 were negatively impacted by the lower customer demand in China for our instrument systems as a result of changes in governmental policy and lower sales in Latin America.
Despite the sales declines in China and Latin America, the need for global access to prescription drugs and the testing of newer and complex biologic drugs increased in the rest of the world.
The 2019 industrial customer sales were negatively impacted by a 6% decline in TA instrument system sales and a 1% decline from the effect of foreign currency translation.
Operating income was $708 million in 2019, a decrease of 4% as compared to 2018.
This decrease can be attributed to lower sales volume, the effect of foreign currency translation and $10 million of severance-related costs in connection with a reduction in workforce that occurred in early 2019, offset by lower variable incentive compensation costs.
In 2018, the Company settled a pension plan obligation and incurred a $46 million expense which reduced the net income per diluted share by $0.39.
In 2017, The Company incurred a $550 million income tax provision related to the 2017 Tax Cuts and Jobs Act (“2017 Tax Act”) which reduced the net income per diluted share by $6.82, and excluding the 2017 Tax Act income tax provision, the Company’s effective tax rate in 2017 would have been 11.0%.
Included in the 2019 net cash flow from operations is $29 million of income tax payments made in the U.S. in relation to the 2017 transition tax liability.
In 2019, $68 million of capital expenditures paid related to the expansion of the Company’s precision chemistry consumable operations in the U.S. The Company has incurred $85 million of costs for this facility through the end of 2019.
two-year
period.
As of December 31, 2019, the Company has a total of $1.7 billion authorized for future repurchases.
In September 2019, the Company issued fixed interest rate senior unsecured notes with an aggregate principal amount of $500 million, of which $200 million of the outstanding notes matures in seven years and the remaining $300 million matures in 10 years.
The Company used the proceeds from the issuance of these senior unsecured notes to repay other outstanding debt and for general corporate purposes.
During 2019 and 2018, the Company entered into $260 million and $300 million, respectively, of
U.S.-to-Euro
In January 2020, the Company entered into a definitive agreement to acquire Andrew Alliance, an innovator in specialty laboratory automation technology, including software and robotics for approximately $80 million.
This acquisition is not expected to have a material effect on the Company sales and expenses in 2020.
In 2019, sales in China were negatively impacted by economic uncertainty caused by certain regulatory changes in our food and pharmaceutical markets.
The 4% increase in sales in Japan was driven by instrument systems, primarily to pharmaceutical and academic and governmental customers, as well as foreign currency translation, which increased Japan’s sales by 2% in 2019.
Sales growth in Asia Other was due primarily to pharmaceutical and academic and governmental customer classes in 2019.
Sales in the U.S. increased by 1% despite large pharmaceutical customers slowing capital spending on our instrument systems.
Sales declines in the rest of the Americas and Europe were broad-based across all product and customer classes due to macroeconomic conditions and political instability, except in Europe where sales to academic and governmental customers grew 8%.
Sales in Europe were also negatively impacted by the effect of foreign currency translation, which decreased sales 4% in 2019.
In 2019, sales to pharmaceutical customers were negatively impacted by the effect of foreign currency translation, which decreased sales to pharmaceutical customers by 2%, as well as a slower release of capital budgets by our customers due to uncertain macroeconomic conditions due to Brexit and regulatory changes in our food and pharmaceutical markets in China.
The decline in sales to industrial customers in 2019 was due to weaker demand for our
##### [Table of Contents](#toc)
Recent acquisitions did not have an impact on sales growth.
During 2018, the demand for our LC-MS instrument systems was somewhat unfavorably impacted by the timing of new product introductions, as many of the Company’s new products were not launched until the second half of 2018 or early in 2019.
In 2017, the demand for instrument system sales was balanced across our LC-MS and TA instrument systems.
Europe’s sales grew 4% and 10% in 2018 and 2017, respectively, and benefited from the effect of foreign currency translation, which added 3% and 2% to sales growth, respectively.
The Company’s 2018 sales were impacted by lower sales growth in India and Europe, resulting from lower customer demand for our instrument systems.
Sales in the Americas grew 3% in 2018 and were flat in 2017.
The Americas’ sales growth in 2017 was negatively impacted by natural disasters in the U.S., Mexico and Puerto Rico, as well as weaker customer sentiment in the first half of 2017.
The growth in both 2018 and 2017 was driven by recent product introductions and rising global regulatory standards in both food and materials markets.
Operating income increased 6% in 2017 as compared to 2016.
This increase was primarily a result of the effect of higher sales volume achieved in 2017, which was somewhat offset by the impact of $13 million of severance costs primarily associated with the closure of a facility in Germany and costs associated with providing U.S. employees with an early retirement transition incentive; an $11 million litigation settlement provision and related costs and a $5 million charge relating to a milestone payment for the licensing of certain intellectual property relating to mass spectrometry technologies yet to be commercialized.
The change in operating income in 2017 as compared with 2016 was also impacted by $4 million of expense in 2017 related to the acceleration of certain stock awards as compared to $7 million of similar expense in 2016.
The Company’s effective tax and net income per diluted share were impacted by the following items:
| | • | | In December 2018, the Company settled a pension plan obligation by making lump-sum cash payments and purchasing annuity contracts for participants to permanently extinguish the pension plan’s |
##### [Table of Contents](#toc)
| | obligations. As a result, the Company recorded a $46 million charge, which consisted of a $6 million cash contribution to the plan and a $40 million non-cash charge related to the reversal of unrecognized actuarial losses recorded in accumulated other comprehensive income in the stockholders’ equity. The $46 million pre-tax charge reduced net income per diluted share by $0.39. |
| | • | | The significant increase in the provision for income taxes for 2017 was a result of the $550 million estimate for the impact of the enactment of the legislation informally referred to as the Tax Cuts and Jobs Act (the “2017 Tax Act”). The 2017 Tax Act changed the U.S. tax system to a territorial system, including broadening measures requiring the taxation of the Company’s historical unremitted foreign earnings through a deemed repatriation. This provision reduced net income per diluted share by $6.82 in 2017, and the Company’s effective tax rate was 11.0% excluding this $550 million provision. As permitted by the U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 118, the Company completed its analysis and calculation of the 2017 Tax Act federal and state transition tax liability during 2018, which remained significantly unchanged. |
The increase in operating cash flow in 2017 was primarily a result of the increase in sales and operating income.
The Company has spent $11 million on this facility through the end of 2018.
During the past three years, the Company has acquired technology to expand its future sales.
In 2017, the Company made a $7 million payment for an investment in a developer of analytical system solutions used to make measurements, predict stability and accelerate product discovery in the routine analytic, process monitoring and quality control release processes for life science and biopharmaceutical markets.
In addition, the Company made a milestone payment of $5 million in 2017 to acquire and license intellectual property.
In September 2016, the Company acquired Rubotherm GmbH for approximately $6 million in cash.
During 2018, the Company had net proceeds from the maturity of short-term investments of $1.8 billion.
The Company has conducted a post-tax reform evaluation of its capital allocation strategy and the Company is currently planning to use its existing cash, cash equivalents and investments, cash flow from operations and its available debt capacity to repurchase up to $4 billion of the Company’s common stock over the next two years.
The Company is currently planning to increase its outstanding debt balances to approximately 2.5 times the
##### [Table of Contents](#toc)
Company’s net debt-to-earnings before interest, taxes, depreciation and amortization ratio to fund a significant portion of these share repurchases.
This new program replaced the remaining amounts available under the April 2018 authorization of $3 billion.
In
##### [Table of Contents](#toc)
In 2017, the sales growth in Asia was driven by double-digit increases in China’s sales across all product and customer classes.
The increase in Asia Other in 2017 was driven by strong sales in India across all product and customer classes.
Japan’s sales in 2017 were driven by recurring revenue sales to governmental and academic customers.
Europe’s sales in 2017 were balanced across all product lines and driven by sales to pharmaceutical, governmental and academic customers.
Sales growth in the U.S. in 2017 was driven by TA instrument system sales and recurring revenues.
In 2017, sales to the rest of the world were impacted by a decrease in demand from industrial customers resulting from recent natural disasters.
In 2017, the growth within our pharmaceutical market was driven by double-digit growth in China, India and Europe.
Sales growth to the industrial market in 2017 was highest in China and India, with modest growth in other regions offset by flat sales in the Americas.
The increase in sales to governmental and academic customers in 2017 was broad-based across all geographies, with double-digit growth in Europe and the Americas.
An excerpt. Shown here: 40 of 248 rewritten, 40 of 122 added and 40 of 130 removed. The counts are complete. For every sentence, read Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in the FY2019 filing and the FY2018 filing.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
29 rewritten, 1,640 added, 3 removed, 20 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
[removed: _Derivative Transactions_][added: Derivative Transactions]
[removed: The Company is exposed to currency price risk on foreign currency exchange rate fluctuations when it translates its non-U.S.] dollar foreign subsidiaries’ financial statements into U.S. dollars, and when any of the Company’s subsidiaries purchase or sell products or services in a currency other than its own currency.
[removed: In 2018,] [added: As of December 31, 2019,] the Company [added: has] entered into three-year interest rate cross-currency swap derivative agreements with a notional value of [removed: $300] [added: $560] million to hedge the variability in the movement of foreign currency exchange rates on a portion of its Euro-denominated net asset investments.
Under hedge accounting, the change in fair value of the derivative that relates to changes in the foreign currency spot rate are recorded in the currency translation adjustment in other comprehensive income and remain in accumulated comprehensive income in stockholders’ [added: (deficit)] equity until the sale or substantial liquidation of the foreign operation.
| | | [removed: December] [added: December] 31, [removed: 2018] [added: 2018] | | | | | | | | [removed: December 31, 2017] | | | | | | |
| | | [removed: Notional Value] [added: Notional Value] | | | | [removed: Fair Value] [added: Fair Value] | | | | [removed: Notional Value] [added: Notional Value] | | | | [removed: Fair Value] [added: Fair Value] | | |
| Other current assets | | $ | [removed: 112,212] [added: 119,576] | | | $ | [removed: 503] [added: 16] | | | $ | [removed: 110,759] [added: 112,212] | | | $ | [removed: 566] [added: 503] | |
| Other current liabilities | | $ | [removed: 40,175] [added: 29,495] | | | $ | [removed: 224] [added: 1,028] | | | $ | [removed: 37,104] [added: 40,175] | | | $ | [removed: 182] [added: 224] | |
| Other assets | | $ | [removed: 300,000] [added: 560,000] | | | $ | [removed: 1,093] [added: 4,485] | | | $ | [removed: —] [added: 300,000] | | | $ | [removed: —] [added: 1,093] | |
| Accumulated other comprehensive income | | | | | | $ | [removed: (1,093] [added: (4,485] | ) | | | | | | $ | [removed: —] [added: (1,093] | [added: )] |
| | | [removed: Financial Statement Classification] [added: Financial Statement Classification] | | | | | | | | | | | | | [added: | |]
| | [removed: | Year] [added: Year] Ended December [removed: 31,] [added: 31,] | | | | | | | | | | | | | [added: | | |]
| | [added: 2019] | [removed: 2018] | | | [added: 2018] | [removed: 2017] | | | [added: 2017] | [removed: 2016] | | | | | [added: | |]
| Foreign currency exchange contracts: | | | | | | | | | | | | | | | [added: | |]
| Realized (losses) gains on closed contracts | | [added: |] Cost of sales | | [added: |] $ | [removed: (6,684] [added: (3,552] | ) | | $ | [removed: 3,894] [added: (6,684] | [added: )] | | $ | [removed: (10,401] [added: 3,894] | [removed: )] |
| Unrealized (losses) gains on open contracts | | [added: |] Cost of sales | | | [removed: (105] | [added: (1,292 |] ) | | | [removed: 1,054] [added: (105] | [added: )] | | | [removed: (883] [added: 1,054] | [removed: )] |
| Cumulative net pre-tax (losses) gains | | [added: |] Cost of sales | | [added: |] $ | [removed: (6,789] [added: (4,844] | ) | | $ | [removed: 4,948] [added: (6,789] | [added: )] | | $ | [removed: (11,284] [added: 4,948] | [removed: )] |
| Interest rate cross-currency swap agreements: | | | | | | | | | | | | | | | [added: | |]
| Interest earned | | [added: |] Interest income | | [added: |] $ | [removed: 2,713] [added: 11,709] | | | $ | [removed: —] [added: 2,713] | | | $ | — | |
| Unrealized gains on open contracts | | [added: |] Stockholders’ [added: (deficit)] equity | | [added: |] $ | [removed: 1,093] [added: 4,485] | | | $ | [removed: —] [added: 1,093] | | | $ | — | |
[removed: Assuming a hypothetical adverse change of 10% in year-end] exchange rates (a strengthening of the U.S. dollar), the fair market value of the foreign currency exchange contracts outstanding as of December 31, [removed: 2018] [added: 2019] would decrease [removed: pre-tax earnings by approximately $15 million.]
[removed: Assuming a hypothetical adverse change of 10% in year-end] exchange rates (a strengthening of the U.S. dollar), the fair market value of the interest rate cross-currency swap agreements outstanding as of December 31, [removed: 2018] [added: 2019] would increase by approximately [removed: $30] [added: $56] million and would be recorded to foreign currency translation in other comprehensive income within stockholders’ [added: (deficit)] equity.
The related impact on interest income would not have a material effect on [removed: pre-tax earnings.]
As of December 31, [removed: 2018,] [added: 2019,] the carrying value of the Company’s cash and cash equivalents approximated fair value.
As of December 31, [removed: 2018,] [added: 2019,] the Company estimates that a hypothetical adverse change of 100 basis points across all maturities would not have a material effect on the fair market value of its portfolio.
As of December 31, [removed: 2018] [added: 2019] and [removed: 2017, $471] [added: 2018, $249] million out of [removed: $1,735] [added: $337] million and [removed: $3,326] [added: $471] million out of [removed: $3,394] [added: $1,735] million, respectively, of the Company’s total cash, cash equivalents and investments were held by foreign subsidiaries.
In addition, [removed: $251] [added: $176] million out of [removed: $1,735] [added: $337] million and [removed: $304] [added: $251] million out of [removed: $3,394] [added: $1,735] million of cash, cash equivalents and investments were held in currencies other than the U.S. dollar at December 31, [removed: 2018] [added: 2019] and [removed: 2017,] [added: 2018,] respectively.
As of December 31, [removed: 2018,] [added: 2019,] the Company [removed: has] [added: had] no holdings in auction rate securities or commercial paper issued by structured investment vehicles.
[removed: Assuming a hypothetical adverse change of 10% in year-end] exchange rates (a strengthening of the U.S. dollar), the fair market value of the Company’s cash, cash equivalents and investments held in currencies other than the U.S. dollar as of December 31, [removed: 2018] [added: 2019] would decrease by approximately [removed: $25] [added: $18] million, of which the majority would be recorded to foreign currency translation in other comprehensive income within stockholders’ [added: (deficit)] equity.
The Company is exposed to currency price risk on foreign currency exchange rate fluctuations when it translates its
non-U.S.
The Company’s principal strategies in managing exposures to changes in foreign currency exchange rates are to (1) naturally hedge the foreign-currency-denominated liabilities on the Company’s balance sheet against
corresponding assets of the same currency, such that any changes in liabilities due to fluctuations in foreign currency exchange rates are typically offset by corresponding changes in assets and (2) mitigate foreign exchange risk exposure of international operations by hedging the variability in the movement of foreign currency exchange rates on a portion of its Euro-denominated net asset investments.
| | | December 31, 2019 | | | | | | | | December 31, 2018 | | | | | | |
Assuming a hypothetical adverse change of 10% in
year-end
pre-tax
earnings by approximately $15 million.
Assuming a hypothetical adverse change of 10% in
year-end
pre-tax
earnings.
Assuming a hypothetical adverse change of 10% in
year-end
| Item | 8: Financial Statements and Supplementary Data |
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules
13a-15(f)
and
15d-15(f)
under the Exchange Act.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in
Internal Control — Integrated Framework (2013)
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
Based on our evaluation under the framework in
Internal Control — Integrated Framework (2013)
, our management, including our chief executive officer and chief financial officer, concluded that our internal control over financial reporting was effective as of December 31, 2019.
The effectiveness of our internal control over financial reporting as of December 31, 2019 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included herein.
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Waters Corporation
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Waters Corporation and its subsidiaries (the “Company”) as of December 31, 2019 and 2018, and the related consolidated statements of operations, of comprehensive income, of stockholders’ equity (deficit) and of cash flows for each of the three years in the period ended December 31, 2019, including the related notes (collectively referred to as the “consolidated financial statements”).
We also have audited the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in
Internal Control — Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019 in conformity with accounting principles generally accepted in the United States of America.
Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in
##### [Table of Contents](#toc)
##### [Table of Contents](#toc)
##### [Table of Contents](#toc)
An excerpt. Shown here: all 29 rewritten, 40 of 1,640 added and all 3 removed. The counts are complete. For every sentence, read Item 7A. Quantitative and Qualitative Disclosures About Market Risk in the FY2019 filing and the FY2018 filing.
Item 1. Business
99 rewritten, 181 added, 208 removed, 139 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
[removed: General][added: General]
[removed: The Company] has pioneered analytical workflow solutions involving liquid chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years.
[removed: The Company primarily designs, manufactures, sells and services high performance liquid chromatography (“HPLC”), ultra performance liquid chromatography (“UPLCTM”] [added: ”] and together with HPLC, referred to as “LC”) and mass spectrometry (“MS”) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans.
These systems are complementary products that are frequently employed together [removed: (“LC-MS”) and sold as integrated instrument systems using common software platforms.]
In addition, the Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its [removed: TATM product line.][added: TA]
[removed: LC-MS] instruments combine a liquid phase sample introduction and separation system with mass spectrometric compound identification and quantification.
[removed: Business Segments][added: Business Segments]
As a result of this evaluation, the Company determined that it has two operating segments: [removed: WatersTM] [added: Waters] and [removed: TATM.][added: TA.]
Information concerning revenues and long-lived assets attributable to each of the Company’s products, services and geographic areas is set forth in Note [removed: 17] [added: 18] in the Notes to the Consolidated Financial Statements, which is incorporated herein by reference.
[removed: Waters] [added: Waters] Products and [removed: Markets][added: Markets]
[removed: _High] [added: High] Performance and Ultra Performance Liquid [removed: Chromatography_][added: Chromatography]
[removed: The most significant end-use] markets for HPLC are those served by the pharmaceutical and life science industries.
In 2004, Waters introduced a novel technology that the Company describes as ultra performance liquid chromatography that utilizes a packing material with small, uniform diameter particles and a specialized instrument, the ACQUITY [removed: UPLCTM, to accommodate the increased pressure and narrower chromatographic bands that are generated by these small and tightly packed particles.][added: UPLC]
[removed: In 2018, the Company introduced the ACQUITYTM ARCTM Bio System, a versatile, iron-free, bio-inert,] quaternary liquid chromatograph specifically engineered to improve bioseparation analytical methods.
[removed: The Company also introduced the ACQUITYTM UPLCTM] PLUS [removed: series in 2018, consisting of the H-Class PLUS, H-Class PLUS Bio and I-Class PLUS] systems, which incorporate foundational enhancements into the legacy systems.
Waters manufactures LC instruments that are offered in configurations that allow for varying degrees of automation, from component configured systems for academic teaching and research applications to fully automated systems for regulated and high sample throughput testing, and that have a variety of detection technologies, from optical-based ultra-violet (“UV”) absorbance, refractive index and fluorescence detectors to a suite of [removed: MS-based detectors, optimized for certain analyses.]
The Company believes that it is one of a few suppliers in the world that [removed: processes] [added: manufactures] silica and polymeric resins, packs columns and distributes its own products.
The Company believes that its ACQUITY UPLC lines of columns are used primarily on its [added: ACQUITY UPLC instrument systems and, furthermore, that its ACQUITY UPLC instruments primarily use ACQUITY UPLC columns.]
[removed: In 2018, the Company introduced the BioResolveTM] RP mAb Polyphenyl columns, which improve the consistency and reliability of the overly complex separations of monoclonal antibodies and antibody-drug conjugates.
[removed: In 2018, the Company introduced the VICAMTM BPATestTM,] [added: ,] which provides a sensitive, precise determination of Bisphenol A in as little as ten minutes.
VICAM also introduced a user-friendly lateral flow zearalenone strip test, the [removed: Zearala-V AQUATM in 2018.]
[removed: _Mass] [added: Mass] Spectrometry and Liquid Chromatography-Mass [removed: Spectrometry_][added: Spectrometry]
A wide variety of instrumental designs fall within the overall category of MS instrumentation, including devices that incorporate quadrupole, ion trap, [removed: time-of-flight (“Tof”), magnetic sector and ion mobility technologies.]
Furthermore, these technologies are often used in tandem [removed: (MS-MS) to maximize the speed and/or efficacy of certain experiments.]
[removed: The Company’s smaller-sized] mass spectrometers, such as the single quadrupole detector (“SQD”) and the tandem quadrupole detector (“TQD”), are often referred to as LC “detectors” and are typically sold as part of an LC system or as an LC system upgrade.
[removed: Larger quadrupole systems, such as the XevoTM TQ and XevoTM TQ-S] instruments, are used primarily for experiments performed for late-stage drug development, including clinical trial testing.
[removed: In 2018, the Company introduced the DART QDaTM system with LiveIDTM,] [added: ,] a direct-from-sample analytical system that verifies sample authenticity or adulteration, specifically for food applications.
[removed: The Company also introduced the XevoTM TQ-GC] mass spectrometer in 2018, which allows laboratories to meet and exceed low [removed: part-per-billion limits of detection when]
[removed: quantifying pesticide residues and other contaminants in food using GC-MS/MS] methods set forth by worldwide regulatory agencies/authorities.
[removed: In addition, the Company introduced the RenataDXTM] screening system, a flow-injection tandem mass spectrometry system for rapid high-throughput analysis of extracted dried blood spots and other human biological matrices.
In response to this development and to further promote the high utilization of these hybrid instruments, the Company has organized its Waters operating segment to develop, manufacture, sell and service integrated [removed: LC-MS systems.]
Based upon reports from independent marketing research firms and publicly-disclosed sales figures from competitors, the Company believes that it is one of the world’s largest manufacturers and distributors of LC and [removed: LC-MS instrument systems, chromatography columns and other consumables and related services.]
[removed: The Company’s newest software technology, UNIFITM,] [added: ,] is a scientific information system that is the culmination of a multi-year effort to substantially bring all of Waters’ preexisting, distinct software systems under one operating system.
[removed: UNIFI joins Waters’ suite of informatics products – EmpowerTM Chromatography Data Software, MassLynxTM Mass Spectrometry Software and NuGenesisTM] Scientific Data Management System, each of which is used to support innovations within world-leading institutions.
In 2018, the Company announced new analysis capabilities across a variety of molecules by integrating UNIFI acquired data from the Company’s [removed: VionTM IMS QTofTM or Xevo GS XS mass spectrometers with Molecular Discovery’s Mass-MetaSite and WebMetabase processing software.]
[removed: _Waters Service_][added: Waters Service]
[removed: The customer] benefits from improved budget control, data-driven technology adoption and accelerated workflow at a site or on a global perspective.
The servicing and support of instruments, software and accessories is an important source of revenue and [removed: represents] [added: represented] over [removed: 30%] [added: 35%] of sales for [removed: Waters.][added: Waters in 2019.]
[removed: Support plans typically involve scheduled] instrument [removed: maintenance and an agreement to promptly repair a non-functioning instrument] in return for a fee described in a contract that is priced according to the configuration of the instrument.
[removed: TA] [added: TA] Products and [removed: Markets][added: Markets]
Waters
TM
The Company primarily designs, manufactures, sells and services high performance liquid chromatography (“HPLC”), ultra performance liquid chromatography (“UPLC
TM
(“LC-MS”)
and sold as integrated instrument systems using common software platforms.
TM
product line.
LC-MS
The most significant
end-use
Waters also has in vitro diagnostic (IVD) labelled products that are used as general-purpose instruments for clinical diagnostic applications, such as newborn screening and therapeutic drug management, in countries where these products are registered.
TM
, to accommodate the increased pressure and narrower chromatographic bands that are generated by these small and tightly packed particles.
In 2018, the Company introduced the ACQUITY ARC
TM
Bio System, a versatile, iron-free,
bio-inert,
The Company also introduced the ACQUITY
UPLC PLUS series in 2018, consisting of the
H-Class
PLUS,
H-Class
PLUS Bio and
I-Class
In 2019, the Company introduced the ACQUITY
TM
Advanced Polymer Chromatography
TM
System, which is the first fully solvent-compatible UPLC system to perform size exclusion, gradient polymer elution and solvent compatible reversed-phase liquid chromatographic separations on a single platform.
The
all-in-one
system gives research scientists greater analytical versatility and speed when conducting research on next-generation polymers.
MS-based
detectors, optimized for certain analyses.
In 2018, the Company introduced the BioResolve
TM
In 2019, the Company introduced the BioResolv SCX mAb Columns and VanGuard
TM
FIT Cartridge technologies.
##### [Table of Contents](#toc)
##### [Table of Contents](#toc)
ACQUITY UPLC instrument systems and, furthermore, that its ACQUITY UPLC instruments primarily use ACQUITY UPLC columns.
In 2016, the Company continued to expand its column chemistry capabilities through the introduction of CORTECSTM C8, CORTECSTM Phenyl, CORTECSTM T3 and CORTECSTM Shield RP18.
Quadrupole time-of-flight (“Q-TofTM”) instruments, such as the Company’s SYNAPTTM G2-S, are often used to analyze the role of proteins in disease processes, an application sometimes referred to as “proteomics”.
In 2016, the Company introduced the XevoTM TQ-XS mass spectrometry system enabled by the newly designed StepWaveTM SX ion guide, which features a unique combination of ion optics, detection and ionization technologies resulting in levels of sensitivity not previously seen.
The Company also introduced SONAR in 2016, which is a new data acquisition technology for use with the Xevo G2-XS that allows for the quantification and identification of lipids, metabolites and proteins in complex samples in a more efficient manner.
##### [Table of Contents](#toc)
In 2016, the Company announced two reference libraries available within UNIFI, the Metabolic Profiling CCS Library and the _Rapi_Fluor-MSTM Glycan GU Scientific Library.
The Company also introduced Symphony Data Pipeline software in 2016, which is a client-server application that automates the movement and transformation of large amounts of LC-MS data to speed up analytical workflows and liberate scientists from mundane yet necessary tasks associated with managing data files.
##### [Table of Contents](#toc)
In 2016, TA introduced a new line of differential scanning calorimeters and thermogravimetric analyzers.
These new Discovery DSC systems feature enhanced sensing technologies resulting in unprecedented performance in baseline flatness, sensitivity, resolution and reproducibility.
In addition, TA introduced the ACS-2 Air Chiller System, ElectroForce 3310 test instrument and DuraPulseTM Stent Graft test instrument in 2016.
In September 2016, the Company acquired all of the outstanding stock of Rubotherm GmbH (“Rubotherm”), a manufacturer of gravimetric analysis systems, for approximately $6 million in cash, $5 million of which was paid at closing and an additional $1 million paid after closing to settle certain liabilities.
Rubotherm develops and manufactures analytical test instruments for thermogravimetric and sorption measurements that are used in both industrial and academic research laboratories in disciplines that include chemistry, material science and engineering.
The Rubotherm acquisition has helped support and further expand product offerings within TA’s thermal analysis business.
##### [Table of Contents](#toc)
##### [Table of Contents](#toc)
Regulation and the European In-Vitro Diagnostic Directive).
##### [Table of Contents](#toc)
However, the Company does not have knowledge that any of its conflict minerals originated from the Democratic Republic of the Congo or adjoining countries.
The results of this and future evaluations may impose additional costs and may introduce new risks related to the Company’s ability to verify the origin of any conflict minerals contained in its products.
##### [Table of Contents](#toc)
each of its three primary technologies.
##### [Table of Contents](#toc)
##### [Table of Contents](#toc)
| | changes in timing and demand for the Company’s products among the Company’s customers and various market sectors, particularly if they should reduce capital expenditures or are unable to obtain funding, as in the cases of governmental, academic and research institutions; the effect of mergers and acquisitions on customer demand for the Company’s products; and the Company’s ability to sustain and enhance service. |
The Company is subject to risks and uncertainties, including, but not limited to, the following:
_The Company’s international operations may be negatively affected by political events, wars or terrorism and regulatory changes, related to either a specific country or a larger region.
These potential political, currency and economic disruptions, as well as foreign currency exchange rate fluctuations, could have a material adverse effect on the Company’s results of operations or financial condition._
Approximately 72% and 71% of the Company’s net sales in 2018 and 2017, respectively, were outside of the United States and were primarily denominated in foreign currencies.
In addition, the Company has considerable manufacturing operations in Ireland and the United Kingdom, as well as significant subcontractors located in Singapore.
As a result, a significant portion of the Company’s sales and operations are subject to certain risks, including adverse developments in the political, regulatory and economic environment, in particular, uncertainty regarding possible changes to foreign and domestic trade policy; the effect of the U.K. voting to exit the European Union as well as the financial difficulties and debt burden experienced by a number of European countries; the instability and potential impact of war or terrorism; the instability and possible dissolution of the Euro as a single currency; sudden movements in a country’s foreign exchange rates due to a change in a country’s sovereign risk profile or foreign exchange regulatory practices; tariffs and other trade barriers; difficulties in staffing and managing foreign operations; and associated adverse operational, contractual and tax consequences.
##### [Table of Contents](#toc)
Additionally, the U.S. dollar value of the Company’s net sales, cost of sales, operating expenses, interest, taxes and net income varies with foreign currency exchange rate fluctuations.
Significant increases or decreases in the value of the U.S. dollar relative to certain foreign currencies, particularly the Euro, Japanese yen and British pound, could have a material adverse effect or benefit on the Company’s results of operations or financial condition.
_Global economic conditions may decrease demand for the Company’s products and harm the Company’s financial results._
The Company is a global business that may be adversely affected by changes in global economic conditions.
These changes in global economic conditions, both inside and outside the U.S., may affect the demand for the Company’s products and services.
An excerpt. Shown here: 40 of 99 rewritten, 40 of 181 added and 40 of 208 removed. The counts are complete. For every sentence, read Item 1. Business in the FY2019 filing and the FY2018 filing.
Item 3. Legal Proceedings
0 rewritten, 1 added, 0 removed, 2 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
Legal Proceedings
Cover and table of contents
62 rewritten, 27 added, 11 removed, 6 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
[removed: UNITED] [added: UNITED] STATES SECURITIES AND EXCHANGE [removed: COMMISSION][added: COMMISSION]
[removed: Washington,] [added: Washington,] D.C. [removed: 20549][added: 20549]
[removed: Form 10-K][added: Form]
| ☑ | [removed: ANNUAL] [added: ANNUAL] REPORT PURSUANT TO SECTION 13 OR [removed: 15(d)] [added: 15(d)] |
| | [removed: OF] [added: OF] THE SECURITIES EXCHANGE ACT OF [removed: 1934] [added: 1934] |
[removed: For] [added: For] the fiscal year ended December 31, [removed: 2018][added: 2019]
| ☐ | [removed: TRANSITION] [added: TRANSITION] REPORT PURSUANT TO SECTION 13 OR [removed: 15(d)] [added: 15(d)] |
| | [removed: OF] [added: OF] THE SECURITIES EXCHANGE ACT OF [removed: 1934] [added: 1934] |
[removed: Commission] [added: Commission] File Number: [removed: 01-14010]
[removed: Waters Corporation][added: Waters Corporation]
[removed: _(Exact] [added: (Exact] name of registrant as specified in its [removed: charter)_][added: charter)]
| [removed: Delaware] [added: Delaware] | | [removed: 13-3668640] [added: 13-3668640] |
| [removed: _(State] [added: (State] or other jurisdiction [removed: of_ _incorporation] [added: of incorporation] or [removed: organization)_] [added: organization)] | | [removed: _(I.R.S. Employer_ _Identification No.)_] [added: (I.R.S. Employer Identification No.)] |
[removed: 34] [added: 34] Maple [removed: Street][added: Street]
[removed: Milford,] [added: Milford,] Massachusetts [removed: 01757][added: 01757]
[removed: _(Address,] [added: (Address,] including zip code, of principal executive [removed: offices)_][added: offices)]
[removed: (508) 478-2000][added: 478-2000]
[removed: _(Registrant’s] [added: (Registrant’s] telephone number, including area [removed: code)_][added: code)]
| Securities registered pursuant to Section 12(b) of the Act: | | [removed: Common Stock, par value $0.01 per share] |
Yes [removed: ☑ No ☐]
Yes [removed: ☐ No ☑]
Yes [removed: ☑ No ☐]
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation [removed: S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).]
Yes [removed: ☑ No ☐]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a [removed: non-accelerated filer, a smaller reporting company, or emerging growth company.]
See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule [removed: 12b-2 of the Exchange Act.]
| Large accelerated filer ☑ | | Accelerated filer ☐ | | Non-accelerated filer ☐ | [removed: |] Smaller reporting company ☐ |
| | | | | | [removed: |] Emerging growth company ☐ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule [removed: 12b-2 of the Act).]
Yes [removed: ☐ No ☑]
State the aggregate market value of the registrant’s common stock held by [removed: non-affiliates of the registrant as of June 30, 2018: $14,912,684,699.]
Indicate the number of shares outstanding of the registrant’s common stock as of February [removed: 22, 2019: 71,512,391][added: 21, 2020: 62,158,045]
[removed: DOCUMENTS] [added: DOCUMENTS] INCORPORATED BY [removed: REFERENCE][added: REFERENCE]
Portions of the registrant’s definitive proxy statement that will be filed for the [removed: 2019] [added: 2020] Annual Meeting of Stockholders are incorporated by reference in Part III.
[removed: WATERS] [added: WATERS] CORPORATION AND [removed: SUBSIDIARIES][added: SUBSIDIARIES]
[removed: ANNUAL] [added: ANNUAL] REPORT ON FORM [removed: 10-K]
[removed: INDEX][added: INDEX]
| [removed: Item No.] [added: Item No.] | | | | | | [removed: Page] [added: Page] | | |
| | | | | [removed: PART I] [added: PART I] | | | | |
| | 1A. | | | [Risk [removed: Factors](#toc612944_2)] [added: Factors](#toc862312_2)] | | | [removed: 11] [added: 12] | |
10-K
or
01-14010
(508)
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | | WAT | | New York Stock Exchange, Inc. |
No
No
No
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
No
non-accelerated
filer, a smaller reporting company, or emerging growth company.
12b-2
of the Exchange Act.
12b-2
of the Act).
No
non-affiliates
of the registrant as of June
, 2019: $14,554,561,947.
10-K
| | 1. | | | [Business](#toc862312_1) | | | 1 | |
| | 2. | | | [Properties](#toc862312_4) | | | 19 | |
| | | | | [Information About Out Executive Officers](#toc862312_7) | | | 20 | |
| | | | | [Signatures](#toc862312_23) | | | 104 | |
10-K 1 d612944d10k.htm 10-K
##### [Table of Contents](#toc)
or
| Name of each exchange on which registered: | | New York Stock Exchange, Inc. |
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
##### [Table of Contents](#toc)
| | 1. | | | [Business](#toc612944_1) | | | 1 | |
| | 2. | | | [Properties](#toc612944_4) | | | 20 | |
| | | | | [Executive Officers of the Registrant](#toc612944_7) | | | 21 | |
| | | | | [Signatures](#toc612944_23) | | | 106 | |
##### [Table of Contents](#toc)
An excerpt. Shown here: 40 of 62 rewritten, all 27 added and all 11 removed. The counts are complete. For every sentence, read Cover and table of contents in the FY2019 filing and the FY2018 filing.
Item 2. Properties
27 rewritten, 2 added, 1 removed, 16 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
Waters Corporation operates [removed: 22] [added: 23] United States facilities and [removed: 72] [added: 67] international facilities, including field offices.
[removed: _Primary] [added: Primary] Facility [removed: Locations_][added: Locations]
| [removed: Location] [added: Location] | | [removed: Function (1)] [added: Function (1)] | | [removed: Owned/Leased] | [added: | Owned/Leased | | |]
| Golden, CO | | [added: |] M, R, S, D, A | | [added: | |] Leased | [added: |]
| New Castle, DE | | [added: |] M, R, S, D, A | | [added: | |] Owned | [added: |]
| Franklin, MA | | [added: |] D | | [added: | |] Leased | [added: |]
| Milford, MA | | [added: |] M, R, S, A | | [added: | |] Owned | [added: |]
| Taunton, MA | | [added: |] M, R | | [added: | |] Owned | [added: |]
| Wakefield, MA | | [added: |] M, R, S, D, A | | [added: | |] Leased | [added: |]
| Eden Prairie, MN | | [added: |] M, R, S, D, A | | [added: | |] Leased | [added: |]
| Nixa, MO | | [added: |] M, S, D, A | | [added: | |] Leased | [added: |]
| Sharpsburg, PA | | [added: |] M, R, S, D, A | | [added: | |] Leased | [added: |]
| Lindon, UT | | [added: |] M, R, S, D, A | | [added: | |] Leased | [added: |]
| Newcastle, England | | [added: |] R, S, D, A | | [added: | |] Leased | [added: |]
| Solihull, England | | [added: |] M,A | | [added: | |] Owned | [added: |]
| Wilmslow, England | | [added: |] M, R, S, D, A | | [added: | |] Owned | [added: |]
| St. Quentin, France | | [added: |] S, A | | [added: | |] Leased | [added: |]
| Bochum, Germany | | [added: |] R, S, A | | [added: | |] Leased | [added: |]
| Huellhorst, Germany | | [added: |] M, R, S, D, A | | [added: | |] Owned | [added: |]
| Budapest, Hungary | | [added: |] R | | [added: | |] Leased | [added: |]
| Wexford, Ireland | | [added: |] M, R, D, A | | [added: | |] Owned | [added: |]
| Etten-Leur, Netherlands | | [added: |] S, D, A | | [added: | |] Owned | [added: |]
| Brasov, Romania | | [added: |] R, A | | [added: | |] Leased | [added: |]
| Singapore | | [added: |] R, S, D, A | | [added: | |] Leased | [added: |]
The Company operates and maintains 11 field offices in the United States and [removed: 61] [added: 56] field offices abroad in addition to sales offices in the primary facilities listed above.
[removed: _Field] [added: Field] Office Locations [removed: (2)_][added: (2)]
| [removed: United States] [added: United States] | | [removed: International] [added: International] | | | | |
Properties
| Cambridge, MA | | | R, S | | | | Leased | |
##### [Table of Contents](#toc)
Item 4. Mine Safety Disclosures
11 rewritten, 8 added, 14 removed, 24 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
O’Connell, [removed: 52,] [added: 53,] has served as a Director of the Company since September 2015, when he assumed the position of President and Chief Executive Officer of the Company.
[removed: Beaudouin, 64,] [added: Keeley Aleman, 43,] was appointed Senior Vice President, General Counsel and Secretary in [removed: February 2016 and was Vice President, General Counsel and Secretary] [added: October] of [removed: the Company since April 2003.][added: 2019.]
Buck, [removed: 55,] [added: 56,] was appointed Senior Vice President and Chief Financial Officer in January 2017.
Carson, [removed: 45,] [added: 46,] was appointed Senior Vice President, Corporate Development in February 2018.
Harrington, [removed: 58,] [added: 59,] was appointed Senior Vice President, Global Markets in February 2016.
Dr. Harrington joined Waters Corporation in 1987 and has held several senior positions with Waters Corporation, [added: including Vice President, Europe and Asia Pacific Operations, Senior Director of US Sales Operations, Director of US Chemistry Sales and General Manager of Phase Separations.]
[removed: Kelly, 56,] [added: Pratt, 50,] was appointed Senior Vice President and President, TA Instruments in [removed: February 2016.][added: August 2019.]
Francis Kim, [removed: 52,] [added: 53,] was appointed Senior Vice President, Global Operations in February 2018.
King, [removed: 62,] [added: 63,] was appointed Senior Vice President, Global Products in July 2017.
Rae, [removed: 61,] [added: 62,] was appointed Senior Vice President, Global Human Resources in February 2016 and was Vice President of Human Resources since October 2005 and Vice President of Worldwide Compensation and Benefits since January 2002.
[removed: PART II][added: PART II]
Mine Safety Disclosures
INFORMATION ABOUT OUR EXECUTIVE OFFICERS
Ms. Aleman joined Waters Corporation in 2006 as the Assistant General Counsel and held various legal roles focusing on business transactions, commercial strategies, international development, compliance, corporate governance and organizational matters.
Prior to joining Waters Corporation she held corporate associate positions at Goodwin Procter, LLP, and Testa, Hurwitz & Thibeault, LLP.
Jonathan M.
Prior to joining Waters Corporation, Mr. Pratt was President of Beckman Coulter Life Sciences.
Additionally, he held senior positions at Pall Corporation, where he was President of its Food & Beverage, Laboratory and ForteBio businesses.
On February 17, 2020, Mr. Kim notified the Company that he will be resigning his position on March 16, 2020.
EXECUTIVE OFFICERS OF THE REGISTRANT
Mark T.
Prior to joining Waters Corporation, he served as Senior Vice President, General Counsel and Secretary of PAREXEL International Corporation, a bio/pharmaceutical services company, from January 2000 to April 2003.
Previously, from May 1985 to January 2000, Mr. Beaudouin served in several senior legal management positions, including Vice President, General Counsel and Secretary of BC International, Inc., a development stage biotechnology company, First Senior Vice President, General Counsel and Secretary of J.
Baker, Inc., a diversified retail company, and General Counsel and Secretary of GenRad, Inc., a high technology test equipment manufacturer.
##### [Table of Contents](#toc)
including Vice President, Europe and Asia Pacific Operations, Senior Director of US Sales Operations, Director of US Chemistry Sales and General Manager of Phase Separations.
Terrance P.
Mr. Kelly has served as President, TA instruments since February 2005.
Mr. Kelly started his career in finance and accounting at ICI in 1985.
He joined DuPont in 1988.
He held various sales and marketing positions with DuPont, and later TA Instruments.
Mr. Kelly joined Waters Corporation in 1996, when TA Instruments was acquired.
##### [Table of Contents](#toc)
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
15 rewritten, 8 added, 11 removed, 7 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
As of February 21, [removed: 2019,] [added: 2020,] the Company had [removed: 86] [added: 80] common stockholders of record.
The Company has not made any sales of unregistered equity securities in the years ended December 31, [removed: 2018, 2017] [added: 2019, 2018] or [removed: 2016.][added: 2017.]
[removed: Securities] [added: Securities] Authorized for Issuance under Equity Compensation [removed: Plans][added: Plans]
[removed: Stock] [added: Stock] Price Performance [removed: Graph][added: Graph]
[removed: _The] [added: The] following performance graph and related information shall not be deemed to be “soliciting material” or to be “filed” with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference into such [removed: filing._][added: filing.]
The following graph compares the cumulative total return on $100 invested as of December 31, [removed: 2013] [added: 2014] (the last day of public trading of the Company’s common stock in fiscal year [removed: 2013)] [added: 2014)] through December 31, [removed: 2018] [added: 2019] (the last day of public trading of the common stock in fiscal year [removed: 2018)] [added: 2019)] in the Company’s common stock, the NYSE Market Index, the SIC Code 3826 Index and the S&P 500 Index.
[removed: COMPARISON] [added: COMPARISON] OF CUMULATIVE TOTAL RETURN SINCE DECEMBER 31, [removed: 2013][added: 2014]
[removed: AMONG] [added: AMONG] WATERS CORPORATION, NYSE MARKET INDEX, SIC CODE 3826 INDEX – LABORATORY ANALYTICAL INSTRUMENTS AND S&P 500 [removed: INDEX][added: INDEX]
[removed: ][added: ]
| | | [removed: 2013] [added: 2014] | | | | [removed: 2014] [added: 2015] | | | | [removed: 2015] [added: 2016] | | | | [removed: 2016] [added: 2017] | | | | [removed: 2017] [added: 2018] | | | | [removed: 2018] [added: 2019] | | | [added: |]
[removed: Purchases] [added: Purchases] of Equity Securities by the [removed: Issuer][added: Issuer]
The following table provides information about purchases by the Company during the three months ended December 31, [removed: 2018] [added: 2019] of equity securities registered by the Company under the Exchange Act (in thousands, except per share data):
| [removed: Period] [added: Period] | | [removed: Total Number] [added: Total Number] of Shares Purchased [removed: (1)] [added: (1)] | | | | [removed: Average] [added: Average] Price Paid per [removed: Share] [added: Share] | | | | [removed: Total] [added: Total] Number of Shares Purchased as Part of Publicly Announced Programs [removed: (2)] [added: (2)] | | | | [removed: Maximum] [added: Maximum] Dollar Value of Shares that May Yet Be Purchased Under the Programs [removed: (2)] [added: (2)] | | |
| (1) | The [removed: Company repurchased 6 thousand shares of common stock at a cost of less than $1 million] [added: Company’s repurchase activity] related to the vesting of restricted stock units during the three months ended December 31, [removed: 2018.] [added: 2019 was insignificant.] |
| (2) | In [removed: April 2018, the Company’s Board of Directors authorized the repurchase of up to $3.5 billion of its outstanding common stock in open market or private transactions over a three-year period. In] January 2019, the Company’s Board of Directors authorized the Company to repurchase up to $4 billion of its outstanding common stock in open market or private transactions over a two-year period. This new program replaced the remaining amounts available under the [removed: April 2018] [added: pre-existing] authorization. |
| WATERS CORPORATION | | $ | 100.00 | | | $ | 119.39 | | | $ | 119.22 | | | $ | 171.39 | | | $ | 167.36 | | | $ | 207.28 | | |
| NYSE MARKET INDEX | | $ | 100.00 | | | $ | 95.91 | | | $ | 107.36 | | | $ | 127.46 | | | $ | 116.06 | | | $ | 145.66 | | |
| SIC CODE INDEX | | $ | 100.00 | | | $ | 111.14 | | | $ | 102.42 | | | $ | 156.71 | | | $ | 165.13 | | | $ | 205.80 | | |
| S&P 500 INDEX | | $ | 100.00 | | | $ | 101.38 | | | $ | 113.51 | | | $ | 138.29 | | | $ | 132.23 | | | $ | 173.86 | | |
| September 29, 2019 to October 26, 2019 | | | 646 | | | $ | 217.06 | | | | 646 | | | $ | 2,112,901 | |
| October 27, 2019 to November 23, 2019 | | | 797 | | | $ | 214.93 | | | | 797 | | | $ | 1,941,602 | |
| November 24, 2019 to December 31, 2019 | | | 1,092 | | | $ | 228.96 | | | | 1,092 | | | $ | 1,691,643 | |
| Total | | | 2,535 | | | $ | 221.52 | | | | 2,535 | | | $ | 1,691,643 | |
##### [Table of Contents](#toc)
| WATERS CORPORATION | | $ | 100.00 | | | $ | 112.72 | | | $ | 134.58 | | | $ | 134.39 | | | $ | 193.19 | | | $ | 188.65 | |
| NYSE MARKET INDEX | | $ | 100.00 | | | $ | 106.75 | | | $ | 102.38 | | | $ | 114.61 | | | $ | 136.07 | | | $ | 123.89 | |
| SIC CODE INDEX | | $ | 100.00 | | | $ | 127.50 | | | $ | 141.59 | | | $ | 130.44 | | | $ | 199.51 | | | $ | 210.24 | |
| S&P 500 INDEX | | $ | 100.00 | | | $ | 113.69 | | | $ | 115.26 | | | $ | 129.05 | | | $ | 157.22 | | | $ | 150.33 | |
##### [Table of Contents](#toc)
| September 30 to October 27, 2018 | | | 128 | | | $ | 182.79 | | | | 128 | | | $ | 2,968,685 | |
| October 28 to November 24, 2018 | | | 1,126 | | | $ | 195.56 | | | | 1,126 | | | $ | 2,748,484 | |
| November 25 to December 31, 2018 | | | 1,466 | | | $ | 189.54 | | | | 1,460 | | | $ | 2,471,785 | |
| Total | | | 2,720 | | | $ | 191.71 | | | | 2,714 | | | $ | 2,471,785 | |
##### [Table of Contents](#toc)
Item 6. Selected Financial Data
23 rewritten, 8 added, 2 removed, 5 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
The statement of operations and balance sheet data is derived from financial statements for the years [added: 2019,] 2018, 2017, [removed: 2016, 2015] [added: 2016] and [removed: 2014.][added: 2015.]
The Company’s financial statements as of December 31, [removed: 2018] [added: 2019] and [removed: 2017,] [added: 2018,] and for each of the three years in the period ended December 31, [removed: 2018] [added: 2019] are included in Part II, Item 8, Financial Statements and Supplementary Data, of this Form [removed: 10-K.]
| [removed: In] [added: In] thousands, except per [removed: share and] [added: share and] employees [removed: data] [added: data] | | [removed: 2018] [added: 2019] | | | | [removed: 2017] [added: 2018] | | | | [removed: 2016] [added: 2017] | | | | [removed: 2015] [added: 2016] | | | | [removed: 2014] [added: 2015] | | |
| [removed: STATEMENT] [added: STATEMENT] OF OPERATIONS [removed: DATA:] [added: DATA:] | | | | | | | | | | | | | | | | | | | | |
| Net sales | | $ | [removed: 2,419,929] [added: 2,406,596] | | | $ | [removed: 2,309,078] [added: 2,419,929] | | | $ | [removed: 2,167,423] [added: 2,309,078] | | | $ | [removed: 2,042,332] [added: 2,167,423] | | | $ | [removed: 1,989,344] [added: 2,042,332] | |
| Income from operations before income taxes | | $ | [removed: 682,146] [added: 678,239] | | | $ | [removed: 641,097] [added: 682,146] | | | $ | [removed: 600,114] [added: 641,097] | | | $ | [removed: 541,918] [added: 600,114] | | | $ | [removed: 490,740] [added: 541,918] | |
| Net income* | | $ | [removed: 593,794] [added: 592,198] | | | $ | [removed: 20,311] [added: 593,794] | | | $ | [removed: 521,503] [added: 20,311] | | | $ | [removed: 469,275] [added: 521,503] | | | $ | [removed: 431,620] [added: 469,275] | |
| Net income per basic common share* | | $ | [removed: 7.71] [added: 8.76] | | | $ | [removed: 0.25] [added: 7.71] | | | $ | [removed: 6.46] [added: 0.25] | | | $ | [removed: 5.70] [added: 6.46] | | | $ | [removed: 5.12] [added: 5.70] | |
| Weighted-average number of basic common shares | | | [removed: 76,992] [added: 67,627] | | | | [removed: 79,793] [added: 76,992] | | | | [removed: 80,786] [added: 79,793] | | | | [removed: 82,336] [added: 80,786] | | | | [removed: 84,358] [added: 82,336] | |
| Net income per diluted common share* | | $ | [removed: 7.65] [added: 8.69] | | | $ | [removed: 0.25] [added: 7.65] | | | $ | [removed: 6.41] [added: 0.25] | | | $ | [removed: 5.65] [added: 6.41] | | | $ | [removed: 5.07] [added: 5.65] | |
| Weighted-average number of diluted common shares and equivalents | | | [removed: 77,618] [added: 68,166] | | | | [removed: 80,604] [added: 77,618] | | | | [removed: 81,417] [added: 80,604] | | | | [removed: 83,087] [added: 81,417] | | | | [removed: 85,151] [added: 83,087] | |
| [removed: BALANCE] [added: BALANCE] SHEET AND OTHER [removed: DATA:] [added: DATA:] | | | | | | | | | | | | | | | | | | | | |
| Cash, cash equivalents and investments | | $ | [removed: 1,735,224] [added: 337,144] | | | $ | [removed: 3,393,701] [added: 1,735,224] | | | $ | [removed: 2,813,032] [added: 3,393,701] | | | $ | [removed: 2,399,263] [added: 2,813,032] | | | $ | [removed: 2,055,388] [added: 2,399,263] | |
| Working capital, including current maturities of debt | | $ | [removed: 2,214,232] [added: 721,157] | | | $ | [removed: 3,663,977] [added: 2,214,232] | | | $ | [removed: 3,115,124] [added: 3,663,977] | | | $ | [removed: 2,649,457] [added: 3,115,124] | | | $ | [removed: 2,236,558] [added: 2,649,457] | |
| Total assets | | $ | [removed: 3,727,426] [added: 2,557,055] | | | $ | [removed: 5,324,354] [added: 3,727,426] | | | $ | [removed: 4,662,059] [added: 5,324,354] | | | $ | [removed: 4,268,677] [added: 4,662,059] | | | $ | [removed: 3,874,690] [added: 4,268,677] | |
| Long-term [removed: debt] [added: debt] | | $ | [removed: 1,148,172] [added: 1,580,797] | | | $ | [removed: 1,897,501] [added: 1,148,172] | | | $ | [removed: 1,701,966] [added: 1,897,501] | | | $ | [removed: 1,493,027] [added: 1,701,966] | | | $ | [removed: 1,237,463] [added: 1,493,027] | |
| Stockholders’ [added: (deficit)] equity* | | $ | [removed: 1,567,258] [added: (216,281] | [added: )] | | $ | [removed: 2,233,788] [added: 1,567,258] | | | $ | [removed: 2,301,949] [added: 2,233,788] | | | $ | [removed: 2,058,851] [added: 2,301,949] | | | $ | [removed: 1,894,666] [added: 2,058,851] | |
| Employees | | | [removed: 7,246] [added: 7,467] | | | | [removed: 7,020] [added: 7,246] | | | | [removed: 6,899] [added: 7,020] | | | | [removed: 6,594] [added: 6,899] | | | | [removed: 6,161] [added: 6,594] | |
This aspect of the new accounting guidance was required to be adopted on a prospective basis for the statement of operations and retroactive restatement [removed: is] [added: was] not permitted.
In [added: 2019,] 2018 and 2017, the Company recognized an excess tax benefit, which decreased income tax expense by $9 [added: million, $9] million and $20 million, respectively, and added [added: $0.14,] $0.11 and $0.24, respectively, to net income per diluted share.
[removed: In addition, in December 2018, the Company settled a pension plan obligation by making lump-sum] cash payments and purchasing annuity contracts for participants to permanently extinguish the pension plan’s obligations.
As a result, the Company recorded a $46 million charge, which consisted of a $6 million cash contribution to the plan and a $40 million [removed: non-cash charge related to the reversal of unrecognized actuarial losses recorded in accumulated other comprehensive income in the stockholders’ equity.]
[removed: The $46 million pre-tax] charge reduced net income per diluted share by $0.39.
10-K.
In addition, in December 2018, the Company settled a pension plan obligation by making
lump-sum
non-cash
charge related to the reversal of unrecognized actuarial losses recorded in accumulated other comprehensive income in the stockholders’ equity.
The $46 million
pre-tax
| | In January 2019, the company adopted new accounting guidance related to the accounting for leases. The new guidance requires lessees to present the assets and liabilities that arise from leases on their balance sheets. The standard required using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019. As a result, the Company recorded a $93 million right-of-use asset as of December 31, 2019. The adoption of this standard did not have a material impact on the Company’s results of operations, cash flows and stockholder’s (deficit) equity. |
##### [Table of Contents](#toc)
| | In 2015, the Company adopted new accounting guidance related to the presentation of debt issuance costs and deferred income taxes, both standards have been applied above retrospectively. Certain debt issuance costs have been reclassified from intangible assets and are presented as a direct deduction from the carrying value of the associated debt. Current deferred tax assets and liabilities have been reclassified as non-current deferred tax assets and liabilities. |
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
0 rewritten, 1 added, 0 removed, 1 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9A. Controls and Procedures
9 rewritten, 14 added, 0 removed, 0 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
[removed: _Evaluation] [added: Evaluation] of Disclosure Controls and [removed: Procedures_][added: Procedures]
The Company’s chief executive officer and chief financial officer (principal executive officer and principal financial officer), with the participation of management, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules [removed: 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this annual report on Form 10-K.]
Based on this evaluation, the Company’s chief executive officer and chief financial officer concluded that the Company’s disclosure controls and procedures were effective as of December 31, [removed: 2018] [added: 2019] (1) to ensure that information required to be disclosed by the Company, including its consolidated subsidiaries, in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its chief executive officer and chief financial officer, to allow timely decisions regarding the required disclosure and (2) to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
[removed: _Management’s] [added: Management’s] Annual Report on Internal Control Over Financial [removed: Reporting_][added: Reporting]
See Management’s Report on Internal Control Over Financial Reporting in Item 8 on page [removed: 49] [added: 46] of this Form [removed: 10-K.]
[removed: _Report] [added: Report] of the Independent Registered Public Accounting [removed: Firm_][added: Firm]
See the report of PricewaterhouseCoopers LLP in Item 8 [added: beginning] on page [removed: 50] [added: 47] of this Form [removed: 10-K.]
[removed: _Changes] [added: Changes] in Internal [removed: Controls] [added: Control] Over Financial [removed: Reporting_][added: Reporting]
[removed: No change was identified in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)] under the Exchange Act) during the quarter ended December 31, [removed: 2018] [added: 2019] that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
13a-15(e)
and
15d-15(e)
under the Exchange Act) as of the end of the period covered by this annual report on Form
10-K.
10-K.
10-K.
No change was identified in the Company’s internal control over financial reporting (as defined in Rules
13a-15(f)
and
15d-15(f)
| Item 9B: Other | Information |
None.
PART III
Item 10. Directors, Executive Officers and Corporate Governance
7 rewritten, 6 added, 2 removed, 7 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
Information regarding the Company’s directors and any material changes to the process by which security holders may recommend nominees to the Board of Directors is contained in the definitive proxy statement for the [removed: 2019] [added: 2020] Annual Meeting of Stockholders under the headings “Election of Directors”, “Directors Meetings and Board Committees”, “Corporate Governance”, “Report of the Audit Committee of the Board of Directors” and “Compensation of Directors and Executive Officers”.
Information regarding compliance with Section 16(a) of the Exchange Act is contained in the Company’s definitive proxy statement for the [removed: 2019] [added: 2020] Annual Meeting of Stockholders under the heading [removed: “Section] [added: “Delinquent Section] 16(a) [removed: Beneficial Ownership Reporting Compliance”.][added: Reports”.]
Information regarding the Company’s Audit Committee and Audit Committee Financial Expert is contained in the definitive proxy statement for the [removed: 2019] [added: 2020] Annual Meeting of Stockholders under the headings “Report of the Audit Committee of the Board of Directors” and “Directors Meetings and Board Committees”.
Information regarding the Company’s executive officers is contained in Part I of this Form [removed: 10-K.]
The Company has adopted a Global Code of Business Conduct & Ethics (the “Code”) that applies to all of the Company’s employees (including its executive officers) and directors and that is in compliance with Item 406 of Regulation [removed: S-K.]
In addition, the Code is available on the Company’s website, [removed: www.waters.com, under the caption “Corporate Governance”.]
The Company’s corporate governance guidelines and the charters of the audit committee, compensation committee, finance committee and nominating and corporate governance committee of the Board of Directors are available on the Company’s website, [removed: www.waters.com, under the caption “Corporate Governance”.]
10-K.
S-K.
www.waters.com
, under the caption “Corporate Governance”.
www.waters.com
, under the caption “Corporate Governance”.
In 2017, the Company adopted a proxy access bylaw provision that allows eligible stockholders or groups of up to 20 stockholders who have held at least 3% of the Company’s common stock continuously for three years to nominate up to two individuals or 20% of the Board of Directors, whichever is greater, for election at the Company’s Annual Meeting of Stockholders, and to have those individuals included in the Company’s proxy materials for that meeting.
The Company believes that the proxy access bylaw adopted by the Company strikes an appropriate balance between providing meaningful proxy access for stockholders and limiting the potential for abuse.
Item 11. Executive Compensation
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
This information is contained in the Company’s definitive proxy statement for the [removed: 2019] [added: 2020] Annual Meeting of Stockholders under the headings “Compensation of Directors and Executive Officers”, “Compensation Committee Interlocks and Insider Participation” and “Compensation Committee Report”.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
7 rewritten, 9 added, 3 removed, 2 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
Except for the Equity Compensation Plan information set forth below, this information is contained in the Company’s definitive proxy statement for the [removed: 2019] [added: 2020] Annual Meeting of Stockholders under the heading “Security Ownership of Certain Beneficial Owners and Management”.
[removed: Equity] [added: Equity] Compensation Plan [removed: Information][added: Information]
The following table provides information as of December 31, [removed: 2018] [added: 2019] about the Company’s common stock that may be issued upon the exercise of options, [removed: warrants,] [added: warrants] and rights under its existing equity compensation plans (in thousands):
| | | [removed: Number] [added: Number] of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights [removed: (1)] [added: (1)] | | | | [removed: Weighted-Average] [added: Weighted-Average] Exercise Price of Outstanding Options, Warrants and Rights [removed: (1)] [added: (1)] | | | | [removed: Number] [added: Number] of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column [removed: (A))] [added: (A))] | | |
| Equity compensation plans approved by security holders | | | [removed: 2,234] [added: 1,861] | | | $ | [removed: 142.47] [added: 158.61] | | | | [removed: 3,005] [added: 2,711] | |
| (1) | Column (a) includes an aggregate of [removed: 444] [added: 406] shares of common stock to be issued upon settlement of restricted stock, restricted stock units and performance stock units. The weighted-average share price in column (b) does not take into account restricted stock, restricted stock units or performance stock units, which do not have an exercise price. |
See Note [removed: 13,] [added: 14,] Stock-Based Compensation, in the Notes to Consolidated Financial Statements for a description of the material features of the Company’s equity compensation plans.
| | | A | | | | B | | | | C | | |
| Total | | | 1,861 | | | $ | 158.61 | | | | 2,711 | |
| Item | 13: Certain Relationships and Related Transactions and Director Independence |
This information is contained in the Company’s definitive proxy statement for the 2020 Annual Meeting of Stockholders under the headings “Directors Meetings and Board Committees”, “Corporate Governance” and “Compensation of Directors and Executive Officers”.
Such information is incorporated herein by reference.
| Item | 14: Principal Accountant Fees and Services |
This information is contained in the Company’s definitive proxy statement for the 2020 Annual Meeting of Stockholders under the headings “Ratification of Selection of Independent Registered Public Accounting Firm” and “Report of the Audit Committee of the Board of Directors”.
Such information is incorporated herein by reference.
PART IV
##### [Table of Contents](#toc)
| | | A | | | | B | | | | C | | |
| Total | | | 2,234 | | | $ | 142.47 | | | | 3,005 | |
Item 15. Exhibits, Financial Statement Schedules
61 rewritten, 42 added, 17 removed, 36 unchanged
Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019
The consolidated financial statements of the Company and its subsidiaries are filed as part of this Form [removed: 10-K and are set forth on pages 52 to 97.]
The report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, dated February [removed: 26, 2019,] [added: 25, 2020,] is set forth [added: beginning] on page [removed: 50] [added: 47] of this Form [removed: 10-K.]
[removed: | | (2) |] [added: Exhibits,] Financial Statement [removed: Schedule: |][added: Schedules]
| | [removed: (3)] [added: (2)] | Exhibits: |
| [removed: Exhibit Number] [added: Exhibit Number] | | [removed: Description] [added: | | Description] of [removed: Document] [added: Document] |
| [added: |] 3.1 | | [added: |] Second Amended and Restated Certificate of Incorporation of Waters Corporation.(1)(P) |
| [added: |] 3.2 | | [added: |] [Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of Waters Corporation, dated as of May 12, 1999.(3)](http://www.sec.gov/Archives/edgar/data/1000697/000104746999030964/0001047469-99-030964.txt) |
| [added: |] 3.3 | | [added: |] [Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of Waters Corporation, dated as of July 27, 2000.(4)](http://www.sec.gov/Archives/edgar/data/1000697/000091205700035253/ex-3_12.txt) |
| [added: |] 3.4 | | [added: |] [Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of Waters Corporation, dated as of May 25, 2001.(5)](http://www.sec.gov/Archives/edgar/data/1000697/000092701602001727/dex313.txt) |
| [added: |] 3.5 | | [added: |] [Amended and Restated Bylaws of Waters Corporation, dated as of December 5, 2017.(29)](http://www.sec.gov/Archives/edgar/data/1000697/000119312517364940/d470585dex31.htm) |
| [added: |] 10.1 | | [added: |] Waters Corporation Retirement Plan.(2)(P)(*) |
| [added: |] 10.2 | | [added: |] [Waters Corporation 2003 Equity Incentive Plan.(6)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013503005751/b48537wcexv4w1.txt) |
| [added: |] 10.3 | | [added: |] [First Amendment to the Waters Corporation 2003 Equity Incentive Plan.(7)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504001254/b48994wcexv10w17.txt) |
| [added: |] 10.4 | | [added: |] [Form of Director Stock Option Agreement under the Waters Corporation 2003 Equity Incentive Plan, as amended.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w27.txt) |
| [added: |] 10.5 | | [added: |] [Form of Director Restricted Stock Agreement under the Waters Corporation 2003 Equity Incentive Plan, as amended.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w28.txt) |
| [added: |] 10.6 | | [added: |] [Form of Executive Officer Stock Option Agreement under the Waters Corporation 2003 Equity Incentive Plan, as amended.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w29.txt) |
| [added: |] 10.7 | | [added: |] [Second Amendment to the Waters Corporation 2003 Equity Incentive Plan.(9)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013505004504/b55598wcexv10w38.htm) |
| [added: |] 10.8 | | [added: |] [Third Amendment to the Waters Corporation 2003 Equity Incentive Plan.(10)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013507001300/b63656wcexv10w48.txt) |
| [added: |] 10.9 | | [added: |] [Amended and Restated Waters 401(k) Restoration Plan, effective January 1, 2008.(11)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013507006667/b67183wcexv10w52.htm) |
| [added: |] 10.10 | | [added: |] [Change of Control/Severance Agreement, dated as of February 27, 2008, between Waters Corporation and Mark T. Beaudouin.(12)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013508001339/b68112wcexv10w53.htm) |
| [added: |] 10.11 | | [added: |] [Change of Control/Severance Agreement, dated as of February 27, 2008, between Waters Corporation and Elizabeth B. Rae.(12)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013508001339/b68112wcexv10w58.htm) |
| [added: |] 10.12 | | [added: |] [Change of Control/Severance Agreement, dated as of February 27, 2008, between Waters Corporation and Eugene G. Cassis.(21)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515067900/d849246dex1014.htm) |
| [removed: Exhibit Number] [added: Exhibit Number] | | [removed: Description] [added: | | Description] of [removed: Document] [added: Document] |
| [added: |] 10.13 | | [added: |] [Amended and Restated Waters Retirement Restoration Plan, effective January 1, 2008.(13)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013509001331/b72903wcexv10w49.htm) |
| [added: |] 10.14 | | [added: |] [Amended and Restated Waters Corporation 1996 Non-Employee Director Deferred Compensation Plan, Effective January 1, 2008.(13)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013509001331/b72903wcexv10w5.htm) |
| [added: |] 10.15 | | [added: |] [2014 Waters Corporation Management Incentive Plan.(21)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515067900/d849246dex1017.htm) |
| [added: |] 10.16 | | [added: |] [Waters Corporation 2009 Employee Stock Purchase Plan.(14)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095012309021422/b76149wcexv4w1.htm) |
| [added: |] 10.17 | | [added: |] [Note Purchase Agreement, dated as of February 1, 2010, between Waters Corporation and the purchases named therein.(15)](http://www.sec.gov/Archives/edgar/data/1000697/000095012310017583/b78684exv10w61.htm) |
| [added: |] 10.18 | | [added: |] [First Amendment to the Note Purchase Agreement, dated as of February 1, 2010.(16)](http://www.sec.gov/Archives/edgar/data/1000697/000095012311046109/b85480exv10w63.htm) |
| [added: |] 10.19 | | [added: |] [Note Purchase Agreement, dated March 15, 2011, between Waters Corporation and the purchases named therein.(16)](http://www.sec.gov/Archives/edgar/data/1000697/000095012311046109/b85480exv10w62.htm) |
| [added: |] 10.20 | | [added: |] [Waters Corporation 2012 Equity Incentive Plan.(17)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512380231/d404655dex41.htm) |
| [added: |] 10.21 | | [added: |] [Form of Waters 2012 Stock Option Agreement - Executive Officers.(18)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512498191/d453660dex101.htm) |
| [added: |] 10.22 | | [added: |] [Form of Waters 2012 Stock Option Agreement - Directors.(18)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512498191/d453660dex102.htm) |
| [added: |] 10.23 | | [added: |] [Form of Waters 2012 Restricted Stock Agreement - Directors.(18)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512498191/d453660dex103.htm) |
| [added: |] 10.24 | | [added: |] [Form of Waters 2012 Restricted Stock Unit Agreement for Executive Officers - Five Year Vesting.(19)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312513469540/d644445dex101.htm) |
| [added: |] 10.25 | | [added: |] [Form of Waters 2012 Restricted Stock Unit Agreement for Executive Officers - One Year Vesting.(19)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312513469540/d644445dex102.htm) |
| [added: |] 10.26 | | [added: |] [Note Purchase Agreement, dated June 30, 2014, between Waters Corporation and the purchases named therein.(20)](http://www.sec.gov/Archives/edgar/data/1000697/000119312514290679/d760078dex101.htm) |
| [added: |] 10.27 | | [added: |] [Change of Control/Severance Agreement, dated as of April 1, 2015, between Waters Corporation and Michael F. Silveira.(22)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515178581/d919579dex101.htm) |
| [added: |] 10.28 | | [added: |] [President and Chief Executive Employment Agreement.(23)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515282127/d84496dex101.htm) |
| [added: |] 10.29 | | [added: |] [Change of Control/Severance Agreement, dated as of September 8, 2015, between Waters Corporation and Christopher J. O’Connell.(23)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515282127/d84496dex102.htm) |
10-K
and are set forth on pages 50 to 95.
10-K.
| | 4.1 | | | [Description of Registrant’s Securities](https://www.sec.gov/Archives/edgar/data/1000697/000119312520048303/d862312dex41.htm) |
| | 10.42 | | | [Note Purchase Agreement, dated as of September 12, 2019, between Waters Corporation and the purchasers named therein.(32)](http://www.sec.gov/Archives/edgar/data/1000697/000119312519245825/d804960dex101.htm) |
| | 10.43 | | | [Form of Performance Stock Unit Award Agreement under the Waters Corporation 2012 Equity Incentive Plan(*)](https://www.sec.gov/Archives/edgar/data/1000697/000119312520048303/d862312dex1043.htm) |
| | 104 | | | Cover Page Interactive Date File (formatted in iXBRL and contained in Exhibit 101). |
| (31) | Incorporated by reference to the Registrant’s Report on Form 10-K/A dated March 1, 2019 (File No. 001-14010). |
| (32) | Incorporated by reference to the Registrant’s Report on Form 8-K dated September 16, 2019 (File No. 001-14010). |
| Item | 16: Form 10-K Summary |
The optional summary in Item 16 has not been included in this Form
10-K.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| /s/ Sherry L. Buck |
| Sherry L. Buck |
| Senior Vice President and |
| Chief Financial Officer |
Date: February 25, 2020
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities indicated on February 25, 2020.
| /s/ Christopher J. O’Connell | | Chairman of the Board of Directors and Chief |
| Christopher J. O’Connell | | Executive Officer (principal executive officer) |
| /s/ Sherry L. Buck | | Senior Vice President and Chief Financial Officer |
| Sherry L. Buck | | (principal financial officer) (principal accounting officer) |
| /s/ Linda Baddour | | Director |
| Linda Baddour | | |
| /s/ Dr. Michael J. Berendt | | Director |
| Dr. Michael J. Berendt | | |
| /s/ Edward Conard | | Director |
| Edward Conard | | |
| /s/ Dr. Laurie H. Glimcher | | Director |
| Dr. Laurie H. Glimcher | | |
| /s/ Gary Hendrickson | | Director |
| Gary Hendrickson | | |
| /s/ Christopher A. Kuebler | | Director |
| Christopher A. Kuebler | | |
| /s/ Flemming Ornskov | | Director |
| Flemming Ornskov | | |
| /s/ JoAnn A. Reed | | Director |
| JoAnn A. Reed | | |
See (c) below.
##### [Table of Contents](#toc)
##### [Table of Contents](#toc)
##### [Table of Contents](#toc)
##### [Table of Contents](#toc)
| (c) | Financial Statement Schedule: |
The following additional financial statement schedule should be considered in conjunction with the consolidated financial statements.
All other schedules have been omitted because the required information is either not applicable or not sufficiently material to require submission of the schedule.
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
For each of the three years in the period ended December 31, 2018
| | | Balance at Beginning of Period | | | | Charged to Provision for Income Taxes* | | | | Other | | | | Balance at End of Period | | |
| Valuation allowance for deferred tax assets: | | | | | | | | | | | | | | | | |
| 2018 | | $ | 62,098 | | | $ | (2,128 | ) | | $ | (6,077 | ) | | $ | 53,893 | |
| 2017 | | $ | 61,225 | | | $ | (6,363 | ) | | $ | 7,236 | | | $ | 62,098 | |
| 2016 | | $ | 68,595 | | | $ | (5,473 | ) | | $ | (1,897 | ) | | $ | 61,225 | |
| * | These amounts have been recorded as part of the income statement provision for income taxes. The income statement effects of these amounts have largely been offset by amounts related to changes in other deferred tax balance sheet accounts. |
| | The change in the valuation allowance during the year ended December 31, 2018 is primarily due to the write-off of a valuation allowance to Retained Earnings for the tax effect related to intra-entity asset transfers. The change in the valuation allowance during the years ended December 31, 2017 and 2016 is primarily due to the effect of foreign currency translation on a valuation allowance related to a net operating loss carryforward. In addition, 2016 includes the release of a valuation allowance related to a foreign tax credit carryforward due to expiration. |
An excerpt. Shown here: 40 of 61 rewritten, 40 of 42 added and all 17 removed. The counts are complete. For every sentence, read Item 15. Exhibits, Financial Statement Schedules in the FY2019 filing and the FY2018 filing.
Item 1B. Unresolved Staff Comments
0 rewritten, 0 added, 2 removed, 0 unchanged
Dropped this year
Read the full itemFY2018 item · filed February 26, 2019
None.
##### [Table of Contents](#toc)
Item 8. Financial Statements and Supplementary Data
0 rewritten, 0 added, 1,418 removed, 0 unchanged
Dropped this year
Read the full itemFY2018 item · filed February 26, 2019
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in _Internal Control_ _— Integrated Framework (2013)_ issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
Based on our evaluation under the framework in _Internal Control_ _— Integrated Framework (2013)_, our management, including our chief executive officer and chief financial officer, concluded that our internal control over financial reporting was effective as of December 31, 2018.
The effectiveness of our internal control over financial reporting as of December 31, 2018 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included herein.
##### [Table of Contents](#toc)
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Waters Corporation
_Opinions on the Financial Statements and Internal Control over Financial Reporting_
We have audited the accompanying consolidated balance sheets of Waters Corporation and its subsidiaries (the “Company”) as of December 31, 2018 and 2017, and the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2018, including the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended December 31, 2018 appearing under Item 15(c) (collectively referred to as the “consolidated financial statements”).
We also have audited the Company’s internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018 in conformity with accounting principles generally accepted in the United States of America.
Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control — Integrated Framework (2013) issued by the COSO.
_Change in Accounting Principle_
As discussed in Note 10 to the consolidated financial statements, the Company changed the manner in which it accounts for share-based payment transactions in 2017.
_Basis for Opinions_
The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting.
Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company’s internal control over financial reporting based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.
Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.
Our audits also included performing such other procedures as we considered necessary in the circumstances.
We believe that our audits provide a reasonable basis for our opinions.
##### [Table of Contents](#toc)
_Definition and Limitations of Internal Control over Financial Reporting_
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
| /s/ PricewaterhouseCoopers LLP |
| Boston, Massachusetts |
| February 26, 2019 |
We have served as the Company’s auditor since 1994.
##### [Table of Contents](#toc)
An excerpt. Shown here: all 0 rewritten, all 0 added and 40 of 1,418 removed. The counts are complete. For every sentence, read Item 8. Financial Statements and Supplementary Data in the FY2018 filing.
Item 9B. Other Information
0 rewritten, 0 added, 3 removed, 0 unchanged
Dropped this year
Read the full itemFY2018 item · filed February 26, 2019
None.
##### [Table of Contents](#toc)
PART III
Item 13. Certain Relationships and Related Transactions and Director Independence
0 rewritten, 0 added, 2 removed, 0 unchanged
Dropped this year
Read the full itemFY2018 item · filed February 26, 2019
This information is contained in the Company’s definitive proxy statement for the 2019 Annual Meeting of Stockholders under the headings “Directors Meetings and Board Committees”, “Corporate Governance” and “Compensation of Directors and Executive Officers”.
Such information is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services
0 rewritten, 0 added, 4 removed, 0 unchanged
Dropped this year
Read the full itemFY2018 item · filed February 26, 2019
This information is contained in the Company’s definitive proxy statement for the 2019 Annual Meeting of Stockholders under the headings “Ratification of Selection of Independent Registered Public Accounting Firm” and “Report of the Audit Committee of the Board of Directors”.
Such information is incorporated herein by reference.
##### [Table of Contents](#toc)
PART IV
Item 16. Form 10-K Summary
0 rewritten, 0 added, 33 removed, 0 unchanged
Dropped this year
Read the full itemFY2018 item · filed February 26, 2019
The optional summary in Item 16 has not been included in this Form 10-K.
##### [Table of Contents](#toc)
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| WATERS CORPORATION |
| /s/ SHERRY L. BUCK |
| Sherry L. Buck |
| _Senior Vice President and_ |
| _Chief Financial Officer_ |
Date: February 26, 2019
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities indicated on February 26, 2019.
| /S/ CHRISTOPHER J. O’CONNELL | | Chairman of the Board of Directors and Chief |
| Christopher J. O’Connell | | Executive Officer (principal executive officer) |
| /S/ SHERRY L. BUCK | | Senior Vice President and Chief Financial Officer |
| Sherry L. Buck | | (principal financial officer) (principal accounting officer) |
| /S/ LINDA BADDOUR | | Director |
| Linda Baddour | | |
| /S/ DR. MICHAEL J. BERENDT | | Director |
| Dr. Michael J. Berendt | | |
| /S/ EDWARD CONARD | | Director |
| Edward Conard | | |
| /S/ DR. LAURIE H. GLIMCHER | | Director |
| Dr. Laurie H. Glimcher | | |
| /S/ GARY HENDRICKSON | | Director |
| Gary Hendrickson | | |
| /S/ CHRISTOPHER A. KUEBLER | | Director |
| Christopher A. Kuebler | | |
| /S/ FLEMMING ORNSKOV | | Director |
| Flemming Ornskov | | |
| /S/ JOANN A. REED | | Director |
| JoAnn A. Reed | | |
| /S/ THOMAS P. SALICE | | Director |
| Thomas P. Salice | | |